Virtual Conference
Pharma Conference 2022

V.D. Sokolova

Russian Presidential Academy of National Economy and Public Administration , Russian Federation

Title: Number needed to treat and incremental costs per responder for biologics and targeted synthetic drugs in adult patients with active psoriatic arthritis in the Russian Federation

Abstract

Background:
Psoriatic arthritis (PsA) is an autoimmune disease – a rare form of inflammatory arthritis with variety of symptoms, which imposes a considerable economic burden to patients and society. A growing range of new medicines is extremely helpful in controlling condition and improving patient's quality-of-life. However, the costs of therapy remain substantial. NNT helps to compare the benefits of various treatments over a baseline risk and to incorporate efficacy results into clinical practice.

Objectives:
To evaluate and compare NNTs for achieving ACR50 and PASI 75 and CpR for biologics (adalimumab, golimumab, guselkumab, ixekizumab, infliximab, netakimab, secukinumab, ustekinumab, certolizumab pegol, etanercept) and targeted synthetic drugs (apremilast, tofacitinib) approved in Russia to treat adults with active PsA.

Methods:
16-week NNTs were calculated as the inverse of risk difference between active treatment and placebo based on the previously published results of a systematic review and network meta-analysis. CpR values were calculated for 16-weeks and one-year treatment periods. The upper limits of 95% credible intervals for NNT and CpR values were used for interpretation and conclusions.

Results:
For ACR50, the lowest NNT was demonstrated by netakimab (no more than 5 patients) followed by etanercept 25 mg and infliximab (up to 7 patients), the highest – by guselkumab (more than 23 patients). For PASI 75, infliximab was ranked as the first with NNT no more than 4 patients followed by netakimab (up to 5 patients) while the last rank was assigned to etanercept 25 mg (more than 96 patients). Netakimab showed the lowest CpR for both outcomes followed by etanercept 25 mg in ACR50 and infliximab in PASI 75 respectively. The highest CpR in achieving ACR50 was attributed to guselkumab, PASI 75 – etanercept 25 mg.

Conclusions:
An individual approach in choosing treatment strategy based on patient profile and features of biologics and targeted synthetic drugs is required.

Biography

Valeriia Sokolova has completed her master’s degree at Queensland University of Technology, Brisbane. She is health economics manager at JSC BIOCAD.

Achievements:
Best worker of 3rd quarter 2019;
Took part in the process of clinical development and market access of original drug for the pathogenetic therapy of cytokine release syndrome in patients with severe course of COVID-19. The drug (levilimab) was guaranteed an accelerated approval by the Russian Ministry of Health and is reimbursed in Russia from the end of 2020;
Prepared a reimbursement dossier for an original oncology drug (cost-effectiveness and budget impact analyses) in 3 weeks instead of 6 months. The drug (prolgolimab) is reimbursed in Russia        from 2021;
Conducted in 4 days a systematic literature review of clinical trials for a meta-analysis of the effectiveness and safety of biologics in the treatment of plaque psoriasis. As a result, the dossier scored highest points in a comprehensive assessment by decision-makers and the original drug (netakimab) is reimbursed in Russia from 2020;
Participant of many research studies conducted within the company and co-author of related publications in Russian scientific journals (links and full text available upon request);
Prepared multiple research abstracts which were exhibited during poster sessions at Virtual ISPOR 2021, Virtual ISPOR Europe 2020, Virtual ISPOR 2020, ISPOR Europe 2019 in Copenhagen and SPOR 2019 in New Orleans (links available upon request).
Speaker at the World Evidence Pricing and Access Congress 2021